翁桁游研究员
教育经历
2002.09-2006.06，中山大学，生物技术，本科
2006.09-2012.06，中山大学，生物化学与分子生物学，博士
工作经历
2012.07-2013.07，中山大学，科研助理
2013.11-2014.12，美国芝加哥大学，博士后
2014.12-2017.11，美国辛辛那提大学，博士后
2017.11-2020.02，美国希望之城贝克曼研究所，助理研究教授
2020.02-2021.04，生物岛实验室，研究员
2021.05至今，广州实验室，研究员
研究简介
翁桁游研究员聚焦于RNA 表观遗传（主要为m6A）修饰的基础及转化研究，发现m6A修饰受组蛋白修饰调控的新机制，并对其在正常和恶性造血中的功能展开了深入的探索，首次发现m6A异常可促进白血病发生发展并开发出靶向m6A阅读器蛋白IGF2BP2的抑制剂。近5年以（共同）第一作者或（共同）通讯作者在Nature、Cell Stem Cell、Cancer Cell（3篇）、Nature Cell Biology等期刊发表SCI论文10余篇，其中6篇入选SCI高被引论文。研究成果被Science Daily、Nature Reviews Genetics、Nature Chemical Biology、Cancer Discovery等科学媒体和学术期刊点评报道，并多次应邀于国内外学术会议上进行口头报告。课题组目前主要研究方向为肿瘤（肺癌、白血病）的表观遗传机制及靶向研究，关注表观遗传事件在肿瘤细胞自身及与微环境互作中的作用及作为肿瘤治疗靶点的潜力。
人才头衔与荣誉奖励
1. 国家重大人才项目获得者（青年）
2. 广州市高层次人才优秀专家
3. 广州市黄埔区优秀人才（创新）
4. 美国血液学会年会杰出摘要奖
5. 第十一届全国核糖核酸（RNA）学术讨论会青年论坛奖
代表性成果
1. Weng H#*, Huang F#, Yu Z#, Chen Z#, Prince E, Kang Y, Zhou K, Li W, Hu J, Fu C, Aziz T, Li H, Li J, Yang Y, Han L, Zhang S, Ma Y, Sun M, Wu H, Zhang Z, Wunderlich M, Robinson S, Braas D, Hoeve JT, Zhang B, Marcucci G, Mulloy JC, Zhou K, Tao HF, Deng X, Horne D, Wei M*, Huang H*, Chen J*. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell 2022, 40(12):1566-1582.e10.
2. Weng H#, Huang H#, Wu H#, Qin X#, Zhao BS#, Dong L#, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M*, He C*, and Chen J*. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell Stem Cell 2018, 22: 191-205. Highlighted by Cell Stem Cell with a Preview article (2018; 22:(139–141).
3. Huang H#, Weng H#, Zhou K#, Wu T#, Zhao BS#, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu Y-C, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan J-L, Qu L, Wei M, Muschen M, Huang G*, He C*, Yang J*, and Chen J*. Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. Nature 2019, 567:414-419.
4. Huang H#, Weng H#, Sun W#, Qin X#, Shi H#, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu YC, Hüttelmaier S, Skibbe J, Su R, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan JL, He C*, Yang J*, Chen J*. Recognition of RNA N6-methyadenosine by IGF2BP proteins Enhances mRNA Stability. Nature Cell Biology 2018, 20:285-295. Featured by Nature Cell Biology with a News & Views article (2018; 20:230–232).
5. Li Z#, Weng H#, Su R#, Weng X#, Zuo Z#, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C*, Chen J*. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell 2017, 31:127-141. Cover Story; Highlighted (Research Watch) by Cancer Discovery (2017; 7(2):OF9).
6. Weng H#, Huang H#, Dong B, Zhao P, Zhou H*, Qu L*. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Research 2014, 74: 4409-4419.
7. Weng H#, Huang H#, Zhao P, Zhou H*, Qu L*. Translational repression of cyclin D3 by a stable G-quadruplex in its 5’ UTR: implications for cell cycle regulation. RNA Biology 2012, 9: 1099-1109.
8. Huang H#, Weng H#, Chen J. m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell 2020, 37: 270-288.
9. Huang H#, Weng H#, Chen J. The Biogenesis and Precise Control of RNA m6A Methylation. Trends in Genetics 2020, 36: 44-52.
10. Zeng C#, Huang W#, Li Y*, Weng H*. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. Journal of Hematology & Oncology 2020, 13:117.